Src kinase induces tumor formation in the c-SRC C57BL/6 mouse - PubMed (original) (raw)
. 2008 Jun 15;122(12):2665-73.
doi: 10.1002/ijc.23445.
Affiliations
- PMID: 18351644
- DOI: 10.1002/ijc.23445
Src kinase induces tumor formation in the c-SRC C57BL/6 mouse
Christina Leah B Kline et al. Int J Cancer. 2008.
Abstract
Src kinase has been linked as a causative agent in the progression of a number of cancers including colon, breast, lung and melanoma. Src protein and activity levels are increased in colorectal cancer and liver metastases arising secondary to colon cancer. However, although Src protein is increased in colon cancer as early as the adenomatous polyp stage, a role for Src in carcinogenesis has not been established. We developed the c-SRC transgenic mouse in the C57BL/6 strain to address the issue of carcinogenesis in cells with high levels of Src expression. The transgene was constructed with the human c-SRC gene downstream of the mouse metallothionein promoter to create zinc inducible gene expression. In these C57BL/6 mice, Src protein was increased in a number of tissues both with and without zinc induction. No additional carcinogenic agent was administered. After 20 months, mice were assessed for tumor development in the liver and GI tract, as well as other organs. Of the mice with the transgene, 15% developed tumors in the liver while no tumors were detected in wild type C57BL/6 mice. A further study was conducted by crossing c-SRC C57BL/6 mice with p21 nullizygous mice to determine the effect of oncogene expression combined with inactivation of the tumor suppressor gene, p21. Addition of the c-SRC transgene to the p21-/- background increased tumor formation almost 3-fold, while it increased metastasis 6-fold. The data from our study show, for the first time, that Src kinase may play a role in carcinogenesis.
(c) 2008 Wiley-Liss, Inc.
Similar articles
- Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer.
Paronetto MP, Farini D, Sammarco I, Maturo G, Vespasiani G, Geremia R, Rossi P, Sette C. Paronetto MP, et al. Am J Pathol. 2004 Apr;164(4):1243-51. doi: 10.1016/S0002-9440(10)63212-9. Am J Pathol. 2004. PMID: 15039213 Free PMC article. - The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
Kanou T, Oneyama C, Kawahara K, Okimura A, Ohta M, Ikeda N, Shintani Y, Okumura M, Okada M. Kanou T, et al. Mol Cancer Res. 2011 Jan;9(1):103-14. doi: 10.1158/1541-7786.MCR-10-0340. Epub 2010 Dec 14. Mol Cancer Res. 2011. PMID: 21156787 - Development of transgenic mice that inducibly express an active form of c-Src in the epidermis.
Matsumoto T, Kiguchi K, Jiang J, Carbajal S, Ruffino L, Beltrán L, Wang XJ, Roop DR, DiGiovanni J. Matsumoto T, et al. Mol Carcinog. 2004 Aug;40(4):189-200. doi: 10.1002/mc.20027. Mol Carcinog. 2004. PMID: 15264211 - SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells.
Shen Y, Jia Z, Nagele RG, Ichikawa H, Goldberg GS. Shen Y, et al. Cancer Res. 2006 Feb 1;66(3):1543-52. doi: 10.1158/0008-5472.CAN-05-3152. Cancer Res. 2006. PMID: 16452211 - Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases.
Han NM, Curley SA, Gallick GE. Han NM, et al. Clin Cancer Res. 1996 Aug;2(8):1397-404. Clin Cancer Res. 1996. PMID: 9816313
Cited by
- Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. Algazi AP, et al. Br J Cancer. 2012 Jan 3;106(1):85-91. doi: 10.1038/bjc.2011.514. Epub 2011 Nov 29. Br J Cancer. 2012. PMID: 22127285 Free PMC article. Clinical Trial. - Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Buettner R, Mesa T, Vultur A, Lee F, Jove R. Buettner R, et al. Mol Cancer Res. 2008 Nov;6(11):1766-74. doi: 10.1158/1541-7786.MCR-08-0169. Mol Cancer Res. 2008. PMID: 19010823 Free PMC article. - Cullin 5 destabilizes Cas to inhibit Src-dependent cell transformation.
Teckchandani A, Laszlo GS, Simó S, Shah K, Pilling C, Strait AA, Cooper JA. Teckchandani A, et al. J Cell Sci. 2014 Feb 1;127(Pt 3):509-20. doi: 10.1242/jcs.127829. Epub 2013 Nov 27. J Cell Sci. 2014. PMID: 24284072 Free PMC article. - HBx induced AFP receptor expressed to activate PI3K/AKT signal to promote expression of Src in liver cells and hepatoma cells.
Zhu M, Guo J, Li W, Xia H, Lu Y, Dong X, Chen Y, Xie X, Fu S, Li M. Zhu M, et al. BMC Cancer. 2015 May 6;15:362. doi: 10.1186/s12885-015-1384-9. BMC Cancer. 2015. PMID: 25943101 Free PMC article. - Oncogenic Ras/Src cooperativity in pancreatic neoplasia.
Shields DJ, Murphy EA, Desgrosellier JS, Mielgo A, Lau SK, Barnes LA, Lesperance J, Huang M, Schmedt C, Tarin D, Lowy AM, Cheresh DA. Shields DJ, et al. Oncogene. 2011 May 5;30(18):2123-34. doi: 10.1038/onc.2010.589. Epub 2011 Jan 17. Oncogene. 2011. PMID: 21242978 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous